Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.

The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.

The valve's sutureless, collapsible frame was built to simplify implantation and help patients recover faster following surgery. This updated version features laser-cut details and was shaped using a zero-pressure fixation process.

The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients.

The new-look Javelin Peripheral IVL Catheter was designed to travel through extremely narrowed blood vessels and target plaques with up to 120 pulses.

Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI.

Hospitals that partner with either company will now experience the benefits of both, learning more about the long-term heart health of their patients than ever before.

Pi-Cardia, an Israeli medtech company, describes ShortCut as the “world’s first dedicated leaflet modification device."

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI. 

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

Almost one in three healthcare organizations allow their people to use AI without formal restrictions. 

The struggling retail pharmacy chain is reportedly being bought out by Sycamore Partners. The deal could be finalized before the end of the week.